D.E. Shaw & Co
SABS icon

D.E. Shaw & Co’s SAB Biotherapeutics SABS Stock Holding History

D.E. Shaw & Co’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-8,318
Closed -$838K – 5678
2021
Q3 		$838K Hold
8,318
– – ﹤0.01% 3747
2021
Q2 		$830K Buy
+8,318
New +$825K ﹤0.01% 3692

Other funds holding SABS

FPB
First PREMIER Bank Sioux Falls, South Dakota $619M AUM 20.21% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
IFAM
Institutional & Family Asset Management Fort Collins, Colorado $654M AUM 12.29% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 21.71% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
V
Veritable Wilmington, Delaware $6.46B AUM 17.32% 1-Year Est. Return

D.E. Shaw & Co's SABS Position: Q4 2021 in Review

D.E. Shaw & Co sold out of SAB Biotherapeutics (SABS) in Q4 2021, closing a stake of 8,318 shares — an estimated $838K sold.

D.E. Shaw & Co first reported a position in SABS in Q2 2021 and held it in 2 quarters. The position peaked at $838K in Q3 2021. 34 funds tracked by Wall St. Rank hold SABS as of Q4 2021.

  • D.E. Shaw & Co reported no remaining SAB Biotherapeutics position as of Q4 2021 after selling out during the quarter.
  • D.E. Shaw & Co sold 8,318 SAB Biotherapeutics shares in Q4 2021, an estimated $838K.
  • D.E. Shaw & Co first reported a position in SAB Biotherapeutics in Q2 2021 and held it in 2 quarters.
  • D.E. Shaw & Co's SAB Biotherapeutics position peaked at $838K in Q3 2021.
  • 34 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q4 2021.

Based on D.E. Shaw & Co's 13F filing for Q4 2021, filed 14 Feb 2022.